Pharmacoeconomic Analysis of the Use of Hepatoprotectors in Management of Drug-Associated Liver Injury Due to Hodgkin's Lymphoma Chemotherapy
Abstract
The data on the pharmacoeconomic research of the use of Remaxol in treatment of drug-associated liver injury due to the chemotherapy in cancer patients are presented. The costs-efficiency method was applied to two groups of the patients with drug-associated liver injury treated according to different schemes. The research showed economical benefits of the Remaxol use.
About the Authors
D. D. Morikov
Irkutsk State Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
E. G. Morikova
Irkut Corporation
Russian Federation
Russian Federation
V. V. Dvornichenko
Irkutsk State Medical University
Russian Federation
Russian Federation
References
1. Демина Е.А. Злокачественные опухоли. 2013; 2: 18-22
2. Шкляев С.С., Павлов В.В. Клин онкогематол 2013; 2: 6: 139-147
3. Руководство по химиотерапии опухолевых заболеваний 2-е изд. / Н.И. Переводчикова (ред.) Практическая медицина, М.: 2005
4. Применение клинико-экономического анализа в медицине. Учебное пособие / А.В. Решетников (ред.), ГЭОТАР-Медиа, М.: 2009
Review
For citations:
Morikov D.D., Morikova E.G., Dvornichenko V.V. Pharmacoeconomic Analysis of the Use of Hepatoprotectors in Management of Drug-Associated Liver Injury Due to Hodgkin's Lymphoma Chemotherapy. Antibiot Khimioter = Antibiotics and Chemotherapy. 2015;60(7-8):23-26. (In Russ.)
Views:
364
Email this article 